Hemant S Murthy
Overview
Explore the profile of Hemant S Murthy including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
92
Citations
640
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Baranwal A, Langer K, Gannamani V, Rud D, Cibich A, Saygin C, et al.
Blood Adv
. 2025 Mar;
PMID: 40085959
Allogeneic stem cell transplant (alloHCT) is considered for all patients with myeloid neoplasms (MN) harboring TP53-mutations (TP53mut). The aim of this international study across 7 transplant centers in USA and...
2.
Munshi P, Olin R, Wall S, McCurdy S, Al-Juhaishi T, Baker J, et al.
Transplant Cell Ther
. 2025 Feb;
PMID: 39961473
Geriatric assessment (GA) may identify vulnerabilities and promote risk-stratification in older adults predisposed to toxicities after autologous (auto), allogeneic (allo) hematopoietic cell transplantation (HCT) and chimeric antigen T-cell therapies (CAR...
3.
Badar T, Knutson K, Knutson K, Foran J, Foran J, Gangat N, et al.
Blood Adv
. 2024 Nov;
9(2):239-243.
PMID: 39571168
No abstract available.
4.
Patel S, Olivero L, Sinclair De Frias J, Anderson S, Pollock B, Lee M, et al.
Otolaryngol Head Neck Surg
. 2024 Oct;
171(6):1925-1927.
PMID: 39396155
National performance metrics ultimately enhance patient decision-making and promote meaningful improvements in health care delivery, which makes having valid and reliable measures essential. This study examined US News and World...
5.
6.
Qie Y, Gadd M, Shao Q, To T, Liu A, Li S, et al.
MedComm (2020)
. 2024 Sep;
5(9):e716.
PMID: 39224539
The challenge of disease relapsed/refractory (R/R) remains a therapeutic hurdle in chimeric antigen receptor (CAR) T-cell therapy, especially for hematological diseases, with chronic lymphocytic leukemia (CLL) being particularly resistant to...
7.
Saifi O, Breen W, Lester S, Rule W, Stish B, Rosenthal A, et al.
Blood Adv
. 2024 Jul;
8(18):4877-4885.
PMID: 39028948
Unirradiated patients with relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma (NHL) who undergo anti-CD19 chimeric antigen receptor T-cell therapy (CART) have a predominant localized pattern of relapse, the significance of which is...
8.
Jain T, Estrada-Merly N, Salas M, Kim S, DeVos J, Chen M, et al.
Blood Adv
. 2024 Jun;
8(16):4281-4293.
PMID: 38916866
We evaluate the impact of donor types on outcomes of hematopoietic cell transplantation (HCT) in myelofibrosis, using the Center for International Blood and Marrow Transplant Research registry data for HCTs...
9.
Jarmi T, Luo Y, Attieh R, Qie Y, Gadd M, Hundal T, et al.
Kidney Int
. 2024 Apr;
105(5):1124-1129.
PMID: 38573274
No abstract available.
10.
Shahid Z, Etra A, Levine J, Riches M, Baluch A, Hill J, et al.
Transplant Cell Ther
. 2024 Mar;
30(5):540.e1-540.e13.
PMID: 38458478
The Blood and Marrow Transplant Clinical Trials Network (BMT-CTN) was established in 2001 to conduct large multi-institutional clinical trials addressing important issues towards improving the outcomes of HCT and other...